摘要
目的:探讨mFOLFOX6方案治疗大肠癌肝转移的临床疗效、不良反应及影响因素。方法:对42例大肠癌肝转移患者采用改良FOLFOX6方案治疗作为观察组,同时随机抽取既往在我院住院并采用传统FOLFOX6方案治疗的大肠癌肝转移患者42例作为对照组。治疗4周期后,评价两组临床疗效及不良反应发生率。结果:观察组和对照组患者的临床有效率分别为57.14%和61.90%(P=0.657),总反应率分别为85.71%和88.10%(P=0.746),两组间无明显差异。观察组患者的中位生存期和疾病进展时间分别为12.1个月和6.2个月,对照组中位生存期和疾病进展时间分别为12.9个月和6.6个月,二者中位生存期及疾病进展时间差异均无统计学意义(P>0.05)。单因素分析结果显示伴有肠梗阻的患者治疗效果较不伴有肠梗阻的患者差,而性别、年龄、原发肿瘤部位、肿瘤的分化程度及肿瘤的大小与化疗效果无关。结论:mFOLFOX6方案治疗大肠癌肝转移的临床疗效与传统FOLFOX6方案相似,但不良反应较后者少,患者具有更好的耐受性,是治疗大肠癌肝转移的理想方案。
Objective：To explore the clinical efficiency,adverse reaction and influential factor of mFOLFOX6 regimen on colorectal cancer with liver metastases.Methods：All 42 patients with colorectal cancer with liver metastases were treated with modified FOLFOX6 regimen as observation group.Meanwhile,we also randomly selected 42 patients with colorectal cancer with liver metastases in our hospital who have recieved traditional FOLFOX6 regimen as control group.After four cycles,we evaluated the clinical efficacy and adverse reaction between two groups.Results：The clinical efficacy rates of observation group and control group were 57.14％ and 61.90％ （P =0.657）,and overall reaction rates were 85.71％ and 88.10％ （P =0.746）,there were no significant differences between the two groups.The median survival and time to progress of patients in observation group were 12.1 months and 6.2 months,and in control group were 12.9 months and 6.6 months（P ＞ 0.05）.Single factor analysis found that chemotherapy effect with intestinal obstruction was worse than that without intestinal obstruction,but chemotherapy effect was related to sex,age,primary tumor location,differentiation and size.Conclusion：The clinical efficacy of mFOLFOX6 regimen in the treatment of colorectal cancer with liver metastases is similar to traditional FOLFOX6 regimen,but adverse reaction is less,patients have better tolerance.Therefore,it is ideal to colorectal cancer with liver metastases.
出处
《现代肿瘤医学》
CAS
2013年第11期2519-2522,共4页
Journal of Modern Oncology
